Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Infection Makes Mosquitoes Immune to Malaria Parasites

Published: Thursday, May 23, 2013
Last Updated: Wednesday, May 22, 2013
Bookmark and Share
Study highlights the potential of using Wolbachia in malaria control.

Researchers established a bacterial infection in mosquitoes that helps fight the parasites that cause malaria. The infected insects could be a significant tool for malaria control.

Malaria is caused by a single-cell parasite called Plasmodium. The parasite infects female mosquitoes when they feed on the blood of an infected person.

Once in the mosquito’s midgut, the parasites multiply and migrate to the salivary glands, ready to infect a new person when the mosquito next bites.

Malaria remains one of the most common infectious diseases in the world. It kills hundreds of thousands each year, mostly young children in sub-Saharan Africa.

Treating bed nets and indoor walls with insecticides is the main prevention strategy in developing countries.

However, the mosquitoes that transmit malaria are slowly becoming resistant to these chemicals, creating an urgent need for new approaches.

Wolbachia is a naturally occurring bacterium that was previously found to block development of Plasmodium parasites in mosquitoes. Wolbachia can be transmitted by an infected female insect to her offspring.

Uninfected females that mate with infected males rarely produce viable eggs-a reproductive dead end that gives infected females a reproductive advantage and helps the bacteria spread quickly.

Wolbachia were successfully used in a field trial to control dengue, another mosquito-borne disease. However, the bacteria don’t pass consistently from a mother to her offspring in Anopheles mosquitoes, which spread malaria.

A team led by Dr. Zhiyong Xi at Michigan State University set out to establish a stable, inherited Wolbachia infection that could block Plasmodium growth in Anopheles.

They focused on Anopheles stephensi, the primary malaria carrier in the Middle East and South Asia.

Their work was funded in part by NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Results appeared on May 10, 2013, in Science.

The researchers injected a strain of Wolbachia derived from another type of mosquito into A. stephensi embryos.

Once matured, the adult females mated with uninfected male mosquitoes to create a stable Wolbachia infection that persisted for 34 generations (the end of the study period).

Uninfected females rarely produced viable eggs with infected males.

To see how well the infected mosquitoes could invade an uninfected A. stephensi population, the researchers tested groups of insects in the laboratory.

When infected females comprised as little as 5% of the population, all the mosquitoes became infected with Wolbachia within 8 generations.

The researchers found that Wolbachia infection reduced the number of malaria parasites in both the mosquito midgut and salivary glands. They hypothesize that Wolbachia infection causes the formation of unstable compounds known as reactive oxygen species, which inhibit parasite development.

This study highlights the potential of using Wolbachia in malaria control. “Wolbachia-based malaria control strategy has been discussed for the last 2 decades,” Xi says.

Xi continued, “Our work is the first to demonstrate Wolbachia can be stably established in a key malaria vector, the mosquito species Anopheles stephensi, which opens the door to use Wolbachia for malaria control.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Wednesday, July 27, 2016
NIH Investment Into HIV Research Expands
Funding has been awarded to six research teams to lead collaborative investigations worldwide toward an HIV cure.
Thursday, July 14, 2016
Drug Might Help Treat Sepsis
A DNA enzyme called Top1 plays a key role in turning on genes that cause inflammation in mouse and human cells in response to pathogens. A drug blocking this enzyme rescued mice from lethal inflammatory responses, suggesting a potential treatment for sepsis.
Wednesday, May 18, 2016
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
Wednesday, May 18, 2016
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Tuesday, May 17, 2016
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
Wednesday, April 27, 2016
Factors Influencing Influenza Vaccine Effectiveness Uncovered
The long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited, new research suggests.
Thursday, April 21, 2016
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
Wednesday, April 20, 2016
Submissions Open for the Cancer Moonshot Program
NCI opens online platform to submit ideas about research for Cancer Moonshot.
Tuesday, April 19, 2016
NIH Awards Grants to Explore Vaccine Adjuvants
NIH awards six grants to explore how combination adjuvants improve vaccines.
Wednesday, April 06, 2016
Experimental Vaccine Protects Against Dengue Virus
An experimental dengue vaccine protected all the volunteers who received it from infection with a live dengue virus.
Wednesday, March 30, 2016
Experimental Ebola Antibody Protects Monkeys
Antibody isolated from Ebola survivor can advance to clinical trials.
Friday, February 26, 2016
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Friday, January 15, 2016
In Uveitis, Bacteria in Gut May Instruct Immune Cells to Attack the Eye
NIH scientists propose novel mechanism to explain autoimmune uveitis.
Wednesday, August 19, 2015
Novel Mechanism to Explain Autoimmune Uveitis Proposed
A new study on mice suggests that bacteria in the gut may provide a kind of training ground for immune cells to attack the eye.
Wednesday, August 19, 2015
Scientific News
Targeting Autoimmunity
Researchers have developed a strategy to treat a rare autoimmune disease which could lead to treatments of other autoimmune diseases.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!